{"id":14851,"date":"2017-11-08T12:09:37","date_gmt":"2017-11-08T11:09:37","guid":{"rendered":"http:\/\/miunidad.eu\/porib.com\/?p=14851"},"modified":"2021-10-20T12:11:27","modified_gmt":"2021-10-20T10:11:27","slug":"casado-lf-hernandez-ja-jarque-i-echave-m-casado-ma-castro-a-2","status":"publish","type":"post","link":"https:\/\/porib.com\/en\/casado-lf-hernandez-ja-jarque-i-echave-m-casado-ma-castro-a-2\/","title":{"rendered":"Casado LF, Hern\u00e1ndez JA, Jarque I, Echave M, Casado MA, Castro A"},"content":{"rendered":"<div class=\"col80\">\n<p class=\"miniatura_foto\" style=\"text-align: justify;\"><strong><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-14157 alignleft\" src=\"https:\/\/porib.com\/wp-content\/uploads\/2021\/09\/ISPOR.jpg\" alt=\"\" width=\"120\" height=\"120\" \/>Casado LF, Hern\u00e1ndez JA, Jarque I, Echave M, Casado MA, Castro A<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<div class=\"col80p\">\n<h6 style=\"text-align: justify;\">Cost-utility of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia<\/h6>\n<h6 style=\"text-align: justify;\"><strong>20th Annual European Congress International Society for Pharmacoeconomics &amp; Outcomes Research (ISPOR). Glasgow, Scotland. 4-8 nov 2017<\/strong><\/h6>\n<p><a href=\"https:\/\/porib.com\/wp-content\/uploads\/2021\/10\/206.pdf\" target=\"_blank\" rel=\"noopener\">POSTER<\/a><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Casado LF, Hern\u00e1ndez JA, Jarque I, Echave M, Casado MA, Castro A &nbsp; &nbsp; Cost-utility of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia 20th Annual European Congress International Society for Pharmacoeconomics &amp; Outcomes Research (ISPOR). Glasgow, Scotland. 4-8 nov 2017 POSTER<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"quote","meta":{"footnotes":""},"categories":[116,933,246],"tags":[],"class_list":["post-14851","post","type-post","status-publish","format-quote","hentry","category-ace-acu-tipo-de-proyecto","category-hematologia-oncohematologia","category-international-society-of-pharmacoeconomics-and-outcomes-research","post_format-post-format-quote"],"translation":{"provider":"WPGlobus","version":"2.10.3","language":"en","enabled_languages":["es","en"],"languages":{"es":{"title":true,"content":true,"excerpt":false},"en":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/14851"}],"collection":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/comments?post=14851"}],"version-history":[{"count":2,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/14851\/revisions"}],"predecessor-version":[{"id":14854,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/14851\/revisions\/14854"}],"wp:attachment":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/media?parent=14851"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/categories?post=14851"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/tags?post=14851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}